Charles Schwab Investment Management Inc. Sells 3,312 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Charles Schwab Investment Management Inc. lessened its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 4.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 75,890 shares of the company’s stock after selling 3,312 shares during the period. Charles Schwab Investment Management Inc. owned about 0.15% of scPharmaceuticals worth $346,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Balanced Rock Investment Advisors LLC grew its position in scPharmaceuticals by 10.3% during the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock valued at $275,000 after buying an additional 5,882 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after buying an additional 52,870 shares during the period. Bank of New York Mellon Corp lifted its position in shares of scPharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after buying an additional 11,269 shares in the last quarter. Bank of Montreal Can bought a new position in shares of scPharmaceuticals during the 2nd quarter valued at approximately $1,544,000. Finally, Rice Hall James & Associates LLC lifted its holdings in scPharmaceuticals by 76.9% during the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SCPH has been the subject of a number of analyst reports. Craig Hallum reduced their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th.

scPharmaceuticals Trading Up 5.4 %

scPharmaceuticals stock opened at $3.31 on Friday. scPharmaceuticals Inc. has a 1 year low of $3.08 and a 1 year high of $6.71. The firm’s 50 day moving average price is $3.85 and its 200-day moving average price is $4.35. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock has a market cap of $165.63 million, a P/E ratio of -1.74 and a beta of 0.14.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.